Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMO | O15229 | 1/20 | 0.49 |
| ▸ | PPARG | P37231 | 7/20 | 0.44 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.44 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.43 |
| ▸ | NR1H2 | P55055 | 6/20 | 0.42 |
| ▸ | NR1H3 | Q13133 | 6/20 | 0.42 |
| ▸ | NR4A2 | P43354 | 2/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | NR4A1 | P22736 | 1/20 | 0.39 |
| ▸ | NR4A3 | Q92570 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3506200 | 0.89 | NR1H2 (0.55) | PPARGNR1H2NR1H3 | |
| SCHEMBL3350743 | 0.88 | NR1H2 (0.46) | NR1H2NR1H3 | |
| SCHEMBL27775786 | 0.84 | KMT2A (0.40) | KMOMEN1POLBKMT2A | |
| SCHEMBL3509660 | 0.82 | MAP4K4 (0.39) | NR1H2NR1H3 | |
| SCHEMBL2448153 | 0.82 | NR1H2 (0.40) | KMONR1H2NR1H3MEN1KMT2A | |
| SCHEMBL3507434 | 0.81 | NR1H2 (0.58) | NR1H2NR1H3 | |
| SCHEMBL2446322 | 0.81 | NR1H3 (0.46) | NR1H2NR1H3 | |
| SCHEMBL3348163 | 0.80 | EGFR (0.38) | NR1H2NR1H3 | |
| SCHEMBL2449201 | 0.79 | FFAR4 (0.43) | NR1H2NR1H3 | |
| SCHEMBL3507078 | 0.79 | NR1H2 (0.48) | NR1H2NR1H3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100273816-A1 | Quinazoline Compounds | WYETH LLC | 2010-10-28 | — | — | US | claimed |
| CN-101679311-A | Quinazoline compound | WYETH CORP | 2010-03-24 | — | — | CN | claimed |
| EP-2142517-A2 | QUINAZOLINE COMPOUNDS | Wyeth (US) | 2010-01-13 | — | — | EP | claimed |
| WO-2009020683-A2 | QUINAZOLINE COMPOUNDS | WYETH (US) | 2009-02-12 | — | — | WO | claimed |
| US-20100273816-A1 | Quinazoline Compounds | WYETH LLC | 2010-10-28 | — | — | US | disclosed |
| CN-101679311-A | Quinazoline compound | WYETH CORP | 2010-03-24 | — | — | CN | disclosed |
| EP-2142517-A2 | QUINAZOLINE COMPOUNDS | Wyeth (US) | 2010-01-13 | — | — | EP | disclosed |
| WO-2009020683-A2 | QUINAZOLINE COMPOUNDS | WYETH (US) | 2009-02-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100273816-A1 | Quinazoline Compounds | NR1H3, NR1H2, NR1I3 | KMO 1850/4885PPARG 63/4885MRGPRX4 41/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.